Pomalyst for Multiple Myeloma: every route to paying for it

The routes, in order

1. 1

   Why this drug and this condition are paired

   ... in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of ...

   From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

   Label on openFDA, read 2026-11-10 · receipt

2. 2

   Medicare Part D: the yearly out-of-pocket threshold

   Found in our data
   CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).

   A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.

   CMS Table V-2, read 2026-11-08

3. 3

   Medicare negotiated price

   Found in our data
   CMS lists $8,650.00 for a 30-day supply, effective 2027-01-01.

   The price CMS lists for the drug, not what you pay. What you pay depends on your plan and your cost sharing.

   CMS negotiated prices, read 2026-11-06

4. 4

   Manufacturer and foundation programs

   Found in our data
   • BMS Access Support status not recorded
   • Bristol Myers Squibb Patient Assistance Foundation (the program's own page) receipt additional REMS requirements

   A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.

5. 5

   Charitable funds for Multiple Myeloma

   Found in our data
   We hold 6 funds for Multiple Myeloma: 1 open and 5 not open, read 2026-11-08. Open: Multiple Myeloma - Medicare Access from HealthWell Foundation.

   Every fund, with its award level, insurance supported and source, is on the Multiple Myeloma page. A fund pays for a condition's costs, not necessarily this drug.

6. 6

   Clinical trial access

   Found in our data
   ClinicalTrials.gov lists 57 recruiting interventional trials that name this ingredient (read 2026-11-07).

   A trial is research, not treatment access for everyone, and a listing is not a recommendation.

   ClinicalTrials.gov, read 2026-11-07 · receipt

Questions